Therapeutic area intelligence for ACE Inhibitor with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 2

Companies

Crescent Pharma Limited →

King Pharmaceuticals →

Assets

ALTACE (Ramipril) →

Crescent →

Recent signals(4)

RegulatoryAugust 6, 2026

FDA Submission Update for ALTACE (Ramipril) by King Pharmaceuticals

King Pharmaceuticals has submitted a supplemental application for ALTACE (Ramipril) with a standard review priority.

StrategyJuly 13, 2026

Crescent Pharma recalls Ramipril 2.5 mg Capsules due to packaging error

Crescent Pharma Limited is recalling a batch of Ramipril 2.5 mg Capsules due to a potential packaging error.

StrategyJune 28, 2026

Crescent Pharma recalls Ramipril 10mg capsules due to manufacturing error

Crescent Pharma Limited is recalling a batch of Ramipril 10mg Capsules due to a potential manufacturing error.

RegulatoryJune 24, 2026

Crescent Pharma recalls Ramipril 5mg capsules due to manufacturing error

Crescent Pharma Limited is recalling a batch of Ramipril 5 mg Capsules due to a potential manufacturing error.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.